Canocapavir - Zhimeng Biopharma
Alternative Names: ZM-H1505RLatest Information Update: 13 Sep 2023
At a glance
- Originator Zhimeng Biopharma
- Class Antivirals; Benzimidazoles; Bromobenzenes; Fluorobenzenes; Ketones; Oxazolidinones; Pyrazoles; Small molecules
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 13 Sep 2023 Chemical structure information added
- 28 Mar 2023 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in USA (PO)
- 02 Aug 2022 Zhimeng Biopharma plans a phase IIa trial in Hepatitis B (Combination therapy, Treatment-experienced) (PO) in China (NCT05484466)